These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3917561)

  • 21. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
    Mallet L; Babin S; Morais JA
    Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
    Thomas KL; La AQ; Punia S; Doroudgar S; Perry PJ
    Ann Clin Psychiatry; 2016 Feb; 28(1):37-42. PubMed ID: 26855984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.
    Kulick SK; Kramer DA
    Ann Emerg Med; 1993 Mar; 22(3):610-2. PubMed ID: 8192712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
    Holroyd S; Overdyke JT
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases.
    Zaccara G; Paganini M; Campostrini R; Arnetoli G; Zappoli R; Moroni F
    Eur Neurol; 1984; 23(2):104-12. PubMed ID: 6426961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Isolated hyperammonemia. A frequent consequence of treatment with sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Galmiche J; Micheletti G; Koehl C; Imler M
    Nouv Presse Med; 1981 Nov; 10(41):3406-7. PubMed ID: 6795590
    [No Abstract]   [Full Text] [Related]  

  • 29. [Sodium valproate, hyperammonemia and hepatic encephalopathy].
    Imler M; Warter JM; Marescaux C
    Gastroenterol Clin Biol; 1982 Dec; 6(12):1042. PubMed ID: 6819177
    [No Abstract]   [Full Text] [Related]  

  • 30. [Carglumic acid for treatment of valproic acid-induced hyperammonaemia in a paediatric patient].
    Gramage Caro T; Vélez-Díaz-Pallarés M; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2012; 36(5):437-8. PubMed ID: 22858088
    [No Abstract]   [Full Text] [Related]  

  • 31. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?
    Chicharro AV; de Marinis AJ; Kanner AM
    Epilepsy Behav; 2007 Nov; 11(3):361-6. PubMed ID: 17845866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
    Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
    J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decrease of valproate-induced hyperammonemia in normal subjects by lipid ingestion.
    Warter JM; Marescaux C; Hirsch E; Rumbach L; Micheletti G; Chabrier G; Imler M
    J Neurol Sci; 1985 Jul; 69(3):285-90. PubMed ID: 3928824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptation of hepatic ammonia metabolism after chronic valproate administration in epileptics treated with phenytoin.
    Marescaux C; Warter JM; Brandt C; Rumbach L; Micheletti G; Chabrier G; Imler M
    Eur Neurol; 1985; 24(3):191-5. PubMed ID: 3922765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Encephalopathy with asterixis induced by sodium valproate. Role of hyperammonemia without hepatic insufficiency].
    Gastaut JL; Mege JL
    Presse Med; 1985 Feb; 14(7):431. PubMed ID: 3157141
    [No Abstract]   [Full Text] [Related]  

  • 36. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 37. Reye-like syndrome associated with valproic acid.
    Sugimoto T; Nishida N; Yasuhara A; Ono A; Sakane Y; Matsumura T
    Brain Dev; 1983; 5(3):334-7. PubMed ID: 6412580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency.
    Leão M
    Neurology; 1995 Mar; 45(3 Pt 1):593-4. PubMed ID: 7898728
    [No Abstract]   [Full Text] [Related]  

  • 40. [Metabolic encephalopathy can be a potentially life-threatening complication from valproic acid].
    Meinardi MC; van den Berg GB; Groenhuijzen A; Driessen JT; Maas HA; Wolfhagen FH
    Ned Tijdschr Geneeskd; 2008 Feb; 152(5):278-82. PubMed ID: 18333544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.